

# Chapter 11

## Other Neoplasms of Myeloid Origin: Histiocytic/Dendritic-Cell and Mast Cell Neoplasms

### ABSTRACT

*Other rare neoplasms may arise from myeloid progenitors, including Histiocytic/Dendritic Neoplasms and mast cell neoplasms. The Classification of both categories in the 5th edition of WHO has some modifications with newly introduced entities. Histiocytic neoplasms exhibit diverse somatic oncogenic alterations. Their clinical presentation ranges from incidental findings to critical illness with severe organ dysfunction. Each subtype has distinct morphologic and immunophenotypic features. However, some overlap exists between the different subtypes. Mastocytosis involves abnormal mast cells accumulating in various organs. It develops as a clonal expansion of mast cells derived by constitutive activation of the KIT receptor. The clinical course varies from asymptomatic to diffuse systemic involvement with comorbidities mainly related to mediators' release.*

### INTRODUCTION

Histiocytic and mast cell neoplasms are two rare categories of myeloid origin. Each encompasses a spectrum of subtypes with heterogeneous clinical courses, pathological features, and prognoses. Histiocyte/dendritic neoplasms have an accumulation of macrophages, monocytes, dendritic cells, interdigitating reticulum cells, or Langerhans cells in affected tissues. (*Durham, 2019*).

The molecular landscape of histiocytosis often involves the MAPK/ERK pathway (RAS-RAF-MEK-ERK) and correlates with phenotypes of various entities. (*Tzankov et al., 2018*)

Mastocytosis results from abnormal mast cells accumulating in various organs. It develops as a clonal expansion of mast cells derived by constitutive activation of the KIT receptor. The clinical course varies from asymptomatic to diffuse systemic involvement with comorbidities mainly related to mediators' release.

The diagnostic approach to both categories integrates pertinent clinical features, morphology, immunohistochemistry of tissue lesions, molecular analysis, and risk assessment. The broad differential diagnosis of each category includes several reactive and neoplastic disorders.

## **HISTIOCYTIC/DENDRITIC NEOPLASMS**

Systemic histiocytic neoplasms originate from hematopoietic stem/progenitor cells (HSPCs) and may be associated with hematological malignancies bearing the same genetic alteration(s).

### **Pathogenesis and Molecular Landscape of Dendritic Cell and Histiocytic Neoplasms**

Driver mutations in particular genes (e.g., N/KRAS) may predispose to an additional clonally related hematological malignancy or secondary histiocytic neoplasm. A multipotent HSPC origin emphasizes the importance of adequate bone marrow staging, molecular analysis, and long-term follow-up of all histiocytosis patients. (Kemps et al., 2021)

Histiocytic neoplasms exhibit diverse somatic oncogenic alterations (*Figure 1*), often involving the MAPK/ERK pathway (RAS-RAF-MEK-ERK) and potentially other pathogenic mechanisms in certain subtypes which provide essential diagnostic and therapeutic channels. (*Durham, 2019*).

42 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

[www.igi-global.com/chapter/other-neoplasms-of-myeloid-origin/350013](http://www.igi-global.com/chapter/other-neoplasms-of-myeloid-origin/350013)

## Related Content

---

### Cancer: Clinical Trial Design and Principles

Rashi Rai, Prudhvilal Bhukya, Muneesh Kumar Barman, Meenakshi Singh, Kailash Chand, Subash C. Sonkarand Manjita Srivastava (2021). *Handbook of Research on Advancements in Cancer Therapeutics* (pp. 627-638).

[www.irma-international.org/chapter/cancer/267061](http://www.irma-international.org/chapter/cancer/267061)

### Mental Health Issues, Wellbeing, and Related Issues Among Caregivers of Individuals With Intellectual Disability

Tanay Maiti (2020). *Developmental Challenges and Societal Issues for Individuals With Intellectual Disabilities* (pp. 114-122).

[www.irma-international.org/chapter/mental-health-issues-wellbeing-and-related-issues-among-caregivers-of-individuals-with-intellectual-disability/236983](http://www.irma-international.org/chapter/mental-health-issues-wellbeing-and-related-issues-among-caregivers-of-individuals-with-intellectual-disability/236983)

### End-of-Life Decision-Making for Severely Ill Newborns: Neonatologists' Point of View and the Greek Legislation

Ilias Chatziioannidis, Evangelia Gkiougki, Abraham Pouliakis, Zoi Iliodromiti, Rozeta Sokou, Takis Vidalis, Theodora Boutsikou, Theodoros Xanthosand Nicoletta Iacovidou (2022). *Research Anthology on Pediatric and Adolescent Medicine* (pp. 178-188).

[www.irma-international.org/chapter/end-of-life-decision-making-for-severely-ill-newborns/298209](http://www.irma-international.org/chapter/end-of-life-decision-making-for-severely-ill-newborns/298209)

### Meeting Patients Where They Are: Using Multimedia and Interactive Voice Technology to Humanize Communication and Engage Patients

Geri Lynn Baumblatt (2017). *Transformative Healthcare Practice through Patient Engagement* (pp. 139-162).

[www.irma-international.org/chapter/meeting-patients-where-they-are/158990](http://www.irma-international.org/chapter/meeting-patients-where-they-are/158990)

### Nanotechnology, Metal Nanoparticles, and Biomedical Applications of Nanotechnology

M. Amin Bhat, B. K. Nayak, Anima Nandaand Imtiyaz H. Lone (2017). *Oncology: Breakthroughs in Research and Practice* (pp. 311-341).

[www.irma-international.org/chapter/nanotechnology-metal-nanoparticles-and-biomedical-applications-of-nanotechnology/158924](http://www.irma-international.org/chapter/nanotechnology-metal-nanoparticles-and-biomedical-applications-of-nanotechnology/158924)